在尿路癌中推进治疗前沿:有针对性的策略和临床影响
Marcela G B Guimarães1, Thiago A Miranda2, Fernanda N C Haum2
1Department of Medical Oncology, Hospital Sírio-Libanês, Brasília, Brazil; Department of Medical Oncology, Hospital de Base do Distrito Federal, Brasília, Brazil.
Chinese clinical oncology
|January 14, 2025
概括
晚期泌尿腺癌 (aUC) 治疗已经进化. 恩福图马布维多丁加上潘布罗利祖马布现在是治疗的标准,改善了aUC患者的存活率.
科学领域:
- 尿瘤学 尿瘤学
- 医学瘤学 医学瘤学
- 临床研究是临床研究.
背景情况:
- 晚期泌尿腺癌 (aUC) 具有显著的临床挑战,存活率有限.
- 基于的化疗历来一直是主要的治疗方法,但其疗效有限.
- 新兴疗法为aUC患者提供了新的希望.
研究的目的:
- 审查aUC治疗的最新进展.
- 总结新疗法的疗效和安全性.
- 要突出不断变化的标准和aUC管理的组合方法.
主要方法:
- 对aUC治疗的第三期临床试验的审查.
- 对免疫检查点抑制剂 (ICI),抗体药物联结剂 (ADC) 和氨酸激酶抑制剂 (TKI) 的分析.
- 专注于一线治疗设置和组合疗法.
主要成果:
- 恩福图马布维多丁 (EV) 与潘布罗利祖马布 ( pembrolizumab) 结合,是aUC的新一线治疗标准.
- 这种组合显著改善了整体存活率 (OS) 和无进展存活率 (PFS) 与化疗相比.
- 其他ADC和向疗法在临床试验中显示出有希望的疗效.
结论:
- 包括ICI和ADC在内的新型疗法正在改变aUC治疗.
- EV和pembrolizumab的组合代表了第一线aUC治疗中的重大突破.
- 对组合策略的持续研究有望进一步改善晚期泌尿腺癌的治疗结果.
更多相关视频
相关概念视频
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


